Immunome stock gets FDA clearance for fifth clinical program
Published on 10/05/2026 at 10:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Immunome stock (ISIN US45257U1088) was last at USD 20.90 on Nasdaq on October 2, 2026, with a market capitalization of USD 2.0 billion. The company then carried a fresh clinical milestone into the market: FDA clearance for IM-1340, an antibody-drug conjugate designed for advanced solid tumors.
FDA clears fifth clinical program
According to Immunome on September 30, 2026, the U.S. Food and Drug Administration cleared the company's Investigational New Drug application for IM-1340. The program targets a transport receptor expressed across neuroendocrine, lung and colorectal tumors and uses Immunome's proprietary HC74 topoisomerase I inhibitor payload.
The company expects to begin a Phase 1 first-in-human study in the fourth quarter of 2026. The open-label, multicenter trial is designed to evaluate safety, tolerability, pharmacokinetics and preliminary antitumor activity in patients with advanced solid tumors.
Loss exceeds second quarter estimate
The clinical update contrasts with the latest reported earnings picture. MarketBeat reported that Immunome posted an adjusted and GAAP loss of USD 0.65 per share for the quarter ended June 30, 2026, versus a consensus loss estimate of USD 0.51. The USD 0.14 shortfall puts the timing of clinical execution alongside cash use and future trial data as key valuation factors.
Consensus target stays above Nasdaq quote
MarketBeat reported on October 4, 2026, that Wall Street Zen downgraded Immunome from Sell to Strong Sell, while the broader consensus remained Moderate Buy. Twelve analysts carried Buy ratings, one rated the stock Hold and one rated it Sell, with an average target of USD 34.25. That target lies 63.9 percent above the Nasdaq price of USD 20.90.
The quote also stood below the 52-week high of USD 30.06 and above the 52-week low of USD 12.41 on October 2, 2026. Trading volume was 1,171,623 shares, giving the clinical milestone a market setting defined by a wide valuation spread rather than a single consensus view.
Next earnings date is November 16
Investing.com lists November 16, 2026, as Immunome's next earnings date. The company is also expected to move IM-1340 into Phase 1 development during the fourth quarter, creating two dated checkpoints for the pipeline story.
IMNM stock stays below yearly high
Immunome stock was last at USD 20.90 on Nasdaq on October 2, 2026, with the 52-week range at USD 12.41 to USD 30.06 and market capitalization at USD 2.0 billion.
Immunome stock key facts
- Company: Immunome, Inc.
- ISIN: US45257U1088
- Ticker: IMNM
- Trading venue: Nasdaq
- Price (as of October 2, 2026, 4:00 p.m. ET): USD 20.90
- Market capitalization: USD 2.0 billion (as of October 2, 2026)
- 52-week range: USD 12.41-30.06 (as of October 2, 2026)
- Sector / Industry: Healthcare / Biotechnology and Medical Research
Upcoming dates for Immunome stock
- November 16, 2026: Next earnings report
